19:06 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Momenta, Global Blood price follow-ons

Momenta raised $200 million Dec. 6 through the sale of 17.4 million shares at $11.50. The price is a 3% premium to Momenta's close of $11.17 on Dec 4. Momenta proposed to raise $150 million...
20:13 , Dec 7, 2018 |  BC Extra  |  Financial News

Momenta, Global Blood price follow-ons

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and Global Blood Therapeutics Inc. (NASDAQ:GBT) have each priced follow-ons, raising a total of $350 million. Momenta raised $200 million late Thursday through the sale of 17.4 million shares at $11.50....
18:26 , Nov 30, 2018 |  BC Week In Review  |  Company News

Boehringer dropping ex-U.S. biosimilars programs

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world. Spokesperson Susan Holz told BioCentury...
00:02 , Nov 29, 2018 |  BC Extra  |  Company News

Boehringer dropping ex-U.S. biosimilars programs

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world. Spokesperson Susan Holz told BioCentury...
20:41 , Oct 5, 2018 |  BC Week In Review  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
23:52 , Oct 1, 2018 |  BC Extra  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
21:26 , Jul 27, 2018 |  BioCentury  |  Regulation

Biosimilar barriers

A coming showdown over anticompetitive contracting practices, coupled with an impending wave of patent expirations, could result in a wave of biosimilar approvals and launches in the U.S. over the next year, according to biosimilars...
20:47 , Jun 12, 2018 |  BC Extra  |  Politics & Policy

BIO chair outraged by nude dancer party

An industry party held during the BIO annual meeting in Boston has been excoriated by the trade organization for featuring nude or partially clothed female dancers. The trade organization’s chairman called on the party’s sponsors...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
20:47 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

FDA approves second generic of thrice-weekly Copaxone

The Sandoz Ltd. unit of Novartis AG (NYSE:NVS; SIX:NOVN) and partner Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said FDA approved an ANDA for thrice-weekly 40 mg/mL Glatopa glatiramer acetate injection as a generic version of multiple sclerosis...